Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Appointed director
HALOZYME THERAPEUTICS, INC. (HALO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 4 LaBarre Michael J. (SVP, CHIEF TECHNICAL OFFICER) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Sold 1,925 shares @ $42.407, valued at $81.6k
Sold 8,075 shares @ $42.407, valued at $342.4k
Exercised 1,925 options to buy @ $18.41, valued at $35.4k
Exercised 8,075 options to buy @ $19.98, valued at $161.3k
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 4 Daly James M (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Sold 10,000 shares @ $43.711, valued at $437.1k
Sold 10,000 shares @ $43.741, valued at $437.4k
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS"
07/27/2023 144 Form 144 - Report of proposed sale of securities:
07/27/2023 4 Torley Helen (PRESIDENT AND CEO) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Sold 10,000 shares @ $42.796, valued at $428k
Sold 10,000 shares @ $42.689, valued at $426.9k
Sold 10,000 shares @ $43.79, valued at $437.9k
Exercised 10,000 options to buy @ $13.87, valued at $138.7k
Exercised 10,000 options to buy @ $13.87, valued at $138.7k
Exercised 10,000 options to buy @ $13.87, valued at $138.7k
07/26/2023 144 Form 144 - Report of proposed sale of securities:
07/25/2023 144 Form 144 - Report of proposed sale of securities:
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/18/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 SC 13G/A VANGUARD GROUP INC reports a 10.3% stake in Halozyme Therapeutics Inc.
05/09/2023 4 Posard Matthew L. (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/09/2023 4 Miyashita Akiko Moni (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/09/2023 4 MATSUI CONNIE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/09/2023 4 Henderson Jeffrey William (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/09/2023 4 Duncan Barbara Gayle (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/09/2023 4 Daly James M (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/09/2023 4 Connaughton Bernadette (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/09/2023 4 BIZZARI JEAN-PIERRE (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.
Txns: Granted 8,065 shares @ $0
Granted 11,371 options to buy @ $31, valued at $352.5k
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS"
05/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/19/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
04/18/2023 144 Form 144 - Report of proposed sale of securities:
03/24/2023 ARS Form ARS - Annual Report to Security Holders:
03/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy